NFE2L2 and chronic obstructive pulmonary disease: Sub-analysis of the COPD group showed no significant differences in Nrf2 or Keap-1 protein or mRNA expression levels between those patients taking inhaled corticosteroids and/or long-acting bronchodilator treatment versus those without these treatments (Supplement Fig. 6).